BusinessSwitzerlandUK

Atlas of cancer cell drug sensitivity launched

30.03.2012 - Two European teams have created huge repositories of cancer genomics data that help predict drug response.

Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale sequencing data of 947 of the 1,200 commercially available human cancer cell lines with the pharmacological profiles of 24 anti-cancer drugs. (Nature 29 March) in a „Cancer Cell Line Encyclopaedia (CCLE)". The cell lines reflect the genetic disturbances that drive cancers,“ said Mark Fishman, Chief of the Novartis Institutes for BioMedical Research (NIBR) that led the study. „Probing cell lines with medicines targeted at specific pathways, as done for the CCLE, provides a powerful tool for design of cancer treatment.“ The data, put into the public domain, will help improve developing targeted therapies. The CCLE provides gene expression data, information on copy number changes as well as DNA sequence variations in about 1,600 cancer-related genes. Additionally, algorithms have been developed to predict drug responses based on the cancer cell’s molecular make-up. When a personal genome is matched against these data an optimised therapy can be obtained for this patient.

In a second study, European researchers from the cancer genome project teamed (coordination EBI, Hinxton) up with US doctors from Massachusetts General Hospital to uncover genetic biomarkers of cancer cells’ drug sensitivity against 130 compounds under clinical and preclinical development (Nature 29.3.). The study was carried out analysing 630 human tumour cell lines representing cancers of epthelial, mesenchymal and hematopoetic origin. The identified cancer subtypes and drug response profiles have been put to the public domain to help researchers engaged in the development of personalised cancer treatments. 

http://www.european-biotechnology-news.com/news/news/2012-01/atlas-of-cancer-cell-drug-sensitivity-launched.html

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SANTHERA80.00 CHF6.74%
  • WILEX2.26 EUR1.80%
  • ADDEX4.07 CHF1.75%

FLOP

  • MOLOGEN7.30 EUR-6.41%
  • 4SC1.16 EUR-3.33%
  • EVOLVA1.27 CHF-2.31%

TOP

  • MAGFORCE6.47 EUR19.8%
  • SANTHERA80.00 CHF15.1%
  • LONZA101.50 CHF9.7%

FLOP

  • WILEX2.26 EUR-31.1%
  • MOLOGEN7.30 EUR-22.8%
  • VITA 343.79 EUR-19.9%

TOP

  • SANTHERA80.00 CHF3802.4%
  • CO.DON2.50 EUR228.9%
  • PAION2.41 EUR186.9%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-66.4%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 20.08.2014